Brexit Impact On Pharmacovigilance Depends On UK MHRA’s Access To EU Databases And Systems
Executive Summary
The UK’s current oversight of pharmacovigilance systems is dependent on its access to several databases and centralized systems designed to serve the single EU market. If the UK cannot have continued access to these systems post Brexit, companies may face duplicative requirements and greater workload.